가바펜틴 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 형태별, 유형별, 용도별, 유통 채널별, 지역별, 경쟁별 세분화(2020-2030년)

Gabapentin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Form, By Type, By Application, By Distribution Channel, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,708,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 8,199,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,926,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계의 가바펜틴 시장은 2024년에 20억 4,000만 달러로 평가되며, 2030년까지 CAGR 5.60%로 성장하며, 28억 3,000만 달러에 달할 것으로 예측됩니다. 항경련제인 가바펜틴은 주로 신경병성 통증 관리 및 간질 부분 발작에 대한 보조 요법으로 사용됩니다. 가바펜틴 세계 시장은 간질 및 다양한 형태의 신경병증성 통증과 같은 만성 신경질환의 유병률 증가와 이러한 질환에 취약한 고령 인구 증가로 인해 크게 성장하고 있습니다.

시장 개요
예측 기간	2026-2030
시장 규모 : 2024년	20억 4,000만 달러
시장 규모 : 2030년	28억 3,000만 달러
CAGR : 2025-2030년	5.60%
가장 빠르게 성장하는 부문	간질
최대 시장	북미

주요 시장 성장 촉진요인

신경병성 통증 질환의 유병률 증가는 가바펜틴이 이러한 질환의 주요 치료 옵션이라는 점에서 세계 가바펜틴 시장을 크게 견인하고 있습니다. 신경 손상이나 질병으로 인한 신경병증성 통증은 종종 만성적이고 쇠약해지는 증상으로 나타나며, 효과적인 약물 치료가 필요합니다.

주요 시장 과제

가바펜틴의 오용, 남용, 오남용 및 오처방 가능성에 대한 규제 당국의 감시 강화는 세계 시장에서 중요한 과제가 되고 있습니다. 이러한 감시 강화로 인해 여러 관할권에서 보다 엄격한 감시 프로토콜을 도입하고 가바펜틴을 규제 약물로 재분류하려는 움직임이 일어나고 있으며, 이는 약물의 가용성과 처방률에 직접적인 영향을 미치고 있습니다.

주요 시장 동향

제약업계가 환자의 복약 순응도 및 치료 결과 개선에 초점을 맞추고 있는 가운데 서방형 제제의 발전은 세계 가바펜틴 시장을 형성하는 중요한 요소입니다. 이러한 혁신적인 제형은 신경병증성 통증과 같은 만성질환을 관리하는 환자들에게 매우 중요한 투약 빈도 감소라는 이점을 제공함으로써 일관된 복약 순응도와 보다 안정적인 증상 조절을 촉진할 수 있습니다.

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 고객의 소리

제5장 세계의 가바펜틴 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율·예측
  • 제형별(정제, 캡슐제, 경구 액제)
  • 유형별(제네릭, 브랜드품)
  • 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
  • 용도별(간질, 신경병증성 통증, 하지불안증후군, 기타)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 가바펜틴 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 가바펜틴 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 유럽 : 국가별 분석
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양지역가바펜틴 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 중동·아프리카가바펜틴 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트
  • 남아프리카공화국

제10장 남미의 가바펜틴 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 남미 : 국가별 분석
  • 브라질
  • 콜롬비아
  • 아르헨티나

제11장 시장 역학

• 촉진요인
• 과제

제12장 시장 동향과 발전

• 합병·인수
• 제품 출시
• 최근 동향

제13장 세계의 가바펜틴 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Zydus Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Limited
• Sun Pharmaceutical Industries Ltd.
• Ascend Laboratories, LLC
• Apotex Inc.
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma.
• Amneal Pharmaceuticals LLC.
• Cipla Ltd.
• BP Pharmaceuticals Laboratories Company

제16장 전략적 제안

제17장 조사회사 소개·면책사항

KSA

영문 목차

영문목차

The Global Gabapentin Market, valued at USD 2.04 Billion in 2024, is projected to experience a CAGR of 5.60% to reach USD 2.83 Billion by 2030. Gabapentin, an anticonvulsant medication, is primarily utilized for managing neuropathic pain and as an adjunct therapy for partial seizures in epilepsy. The global market for gabapentin is significantly driven by the increasing prevalence of chronic neurological conditions, such as epilepsy and various forms of neuropathic pain, alongside the expanding geriatric population, which is more susceptible to these disorders.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 2.04 Billion
Market Size 2030	USD 2.83 Billion
CAGR 2025-2030	5.60%
Fastest Growing Segment	Epilepsy
Largest Market	North America

Key Market Drivers

The rising prevalence of neuropathic pain disorders significantly drives the global gabapentin market, as the medication is a primary treatment option for these conditions. Neuropathic pain, resulting from nerve damage or disease, often presents as chronic and debilitating, necessitating effective pharmaceutical interventions. According to a February 2024 article published in PubMed Central titled 'Shedding light on neuropathic pain: Current and emerging tools for diagnosis, screening, and quantification', the estimated prevalence of neuropathic pain in Europe is 7%-8%.

Key Market Challenges

Increasing regulatory scrutiny regarding gabapentin's potential for misuse, abuse, and off-label prescribing presents a significant challenge to the global market. This heightened oversight has prompted various jurisdictions to implement stricter monitoring protocols or reclassify gabapentin as a controlled substance, which directly affects its accessibility and prescription rates. Such reclassification introduces administrative complexities for healthcare providers and pharmacists, increasing the burden associated with prescribing and dispensing.

Key Market Trends

Advancements in Extended-Release Formulations are a significant factor shaping the global gabapentin market, driven by the pharmaceutical industry's focus on enhancing patient compliance and therapeutic outcomes. These innovative formulations offer advantages by reducing the frequency of dosing, which is crucial for individuals managing chronic conditions such as neuropathic pain, thereby promoting consistent medication adherence and more stable symptom control.

Key Market Players

• Zydus Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Limited
• Sun Pharmaceutical Industries Ltd.
• Ascend Laboratories, LLC
• Apotex Inc.
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma.
• Amneal Pharmaceuticals LLC.
• Cipla Ltd.
• BP Pharmaceuticals Laboratories Company

Report Scope:

In this report, the Global Gabapentin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gabapentin Market, By Form:

• Tablet
• Capsule
• Oral Solution

Gabapentin Market, By Type:

• Generic
• Branded

Gabapentin Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Gabapentin Market, By Application:

• Epilepsy
• Neuropathic Pain
• Restless Legs Syndrome
• Others

Gabapentin Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Gabapentin Market.

Available Customizations:

Global Gabapentin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gabapentin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Form (Tablet, Capsule, Oral Solution)
  • 5.2.2. By Type (Generic, Branded)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.4. By Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Gabapentin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Form
  • 6.2.2. By Type
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Application
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gabapentin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Form
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Distribution Channel
      • 6.3.1.2.4. By Application
  • 6.3.2. Canada Gabapentin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Form
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Distribution Channel
      • 6.3.2.2.4. By Application
  • 6.3.3. Mexico Gabapentin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Form
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Distribution Channel
      • 6.3.3.2.4. By Application

7. Europe Gabapentin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Form
  • 7.2.2. By Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Application
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Gabapentin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Form
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Distribution Channel
      • 7.3.1.2.4. By Application
  • 7.3.2. France Gabapentin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Form
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Distribution Channel
      • 7.3.2.2.4. By Application
  • 7.3.3. United Kingdom Gabapentin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Form
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Distribution Channel
      • 7.3.3.2.4. By Application
  • 7.3.4. Italy Gabapentin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Form
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Distribution Channel
      • 7.3.4.2.4. By Application
  • 7.3.5. Spain Gabapentin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Form
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Distribution Channel
      • 7.3.5.2.4. By Application

8. Asia Pacific Gabapentin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Form
  • 8.2.2. By Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Application
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Gabapentin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Form
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Distribution Channel
      • 8.3.1.2.4. By Application
  • 8.3.2. India Gabapentin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Form
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Distribution Channel
      • 8.3.2.2.4. By Application
  • 8.3.3. Japan Gabapentin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Form
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Distribution Channel
      • 8.3.3.2.4. By Application
  • 8.3.4. South Korea Gabapentin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Form
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Distribution Channel
      • 8.3.4.2.4. By Application
  • 8.3.5. Australia Gabapentin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Form
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Distribution Channel
      • 8.3.5.2.4. By Application

9. Middle East & Africa Gabapentin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Form
  • 9.2.2. By Type
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Application
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Gabapentin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Form
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Distribution Channel
      • 9.3.1.2.4. By Application
  • 9.3.2. UAE Gabapentin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Form
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Distribution Channel
      • 9.3.2.2.4. By Application
  • 9.3.3. South Africa Gabapentin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Form
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Distribution Channel
      • 9.3.3.2.4. By Application

10. South America Gabapentin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Form
  • 10.2.2. By Type
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Application
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Gabapentin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Form
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Distribution Channel
      • 10.3.1.2.4. By Application
  • 10.3.2. Colombia Gabapentin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Form
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Distribution Channel
      • 10.3.2.2.4. By Application
  • 10.3.3. Argentina Gabapentin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Form
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Distribution Channel
      • 10.3.3.2.4. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Gabapentin Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zydus Pharmaceuticals, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Glenmark Pharmaceuticals Limited
• 15.3. Sun Pharmaceutical Industries Ltd.
• 15.4. Ascend Laboratories, LLC
• 15.5. Apotex Inc.
• 15.6. Teva Pharmaceutical Industries Ltd.
• 15.7. Aurobindo Pharma.
• 15.8. Amneal Pharmaceuticals LLC.
• 15.9. Cipla Ltd.
• 15.10. BP Pharmaceuticals Laboratories Company

16. Strategic Recommendations

17. About Us & Disclaimer

관련자료